OBJECTIVE: The aim of this study was to explore the clinical role of serum interleukin (IL)-17 in patients with non-small-cell lung cancer (NSCLC). MATERIALS AND METHOD: Serum specimens from 128 patients with NSCLC and 60 healthy controls were collected. The concentrations of IL-17 were measured using enzyme-linked immunosorbent assay. RESULTS: Serum IL-17 levels were higher in the NSCLC group in comparison with the control group (p < 0.01). With a cut-off value of 16 pg/ml, IL-17 showed a good diagnostic performance for NSCLC. Multivariate survival analysis indicated that IL-17 was an independent prognostic factor in NSCLC. CONCLUSION: Measurement of IL-17 might be a useful diagnostic and prognostic value for patients with NSCLC.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2014) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: